When the FDA announced plans to expand real-time clinical trials and use AI in early-stage drug studies, it was pitched as a faster, more modern approach to medicine. For Black patients, who are underrepresented in research, the shift raises a bigger question: Will it improve equity in clinical trials or worsen disparities?
The FDA’s plan would let researchers track patient data in real time instead of waiting until trials end. The agency says AI could help flag safety concerns, spot patterns, and speed up decision-making in early testing. FDA Commissioner Marty Makary called the effort a way to cut years from the drug development process.
For many patients, especially those who’ve historically not been studied, real-time participation could actually make trials easier. Traditional clinical trials often mean repeated doctor visits, lots of paperwork, transportation challenges, and time off work. Those barriers hit Black communities especially hard, especially for those juggling caregiving responsibilities or shift work.
New digital tools could change that by allowing people to send health updates from home via smartphones, wearables, or telehealth. Researchers have long said that moving trials outside hospitals could help more diverse groups participate.
That matters because Black patients are still underrepresented in clinical trials. One study published in Communications Medicine found that only about 23 percent of FDA drug trials in 2023 included enough Black participants to reflect the population. Other research shows enrollment is often far below what’s needed for fair representation.
RELATED: How AI Can Increase Clinical Trial Participation
The gap in Black participation in clinical trials has real consequences. Clinical trials shape drug dosage, identify side effects, and assess safety. When Black patients aren’t included, treatments may not be fully tested across different populations.
AI could help fix some of this. FDA officials say it may improve recruitment, spot underserved groups, and track how people are doing during trials. But experts warn it’s not that simple — AI can reflect bias if it’s trained on limited or unbalanced data.
That concern is already showing up in healthcare. Researchers have found racial bias in some medical algorithms used for hospital care decisions and diagnostic support. In clinical trials, the stakes are even higher because AI may influence who gets included, flagged for risk, or allowed to stay in a study.
There are also privacy concerns. Real-time tracking can involve continuous data collection via apps, wearables, and electronic records shared among hospitals and drug companies. For many Black Americans, trust in the medical system is still shaped by past abuses like the Tuskegee Syphilis study and the case of Henrietta Lacks, where cells were used without consent. That makes transparency and consent especially important.
Some researchers also question whether this is really a breakthrough or just a way to make trials more efficient. Critics say bigger issues, such as unequal access to trial sites and inconsistent oversight, won’t be solved by technology alone.
RELATED: Breakthrough Trials: How AI Immunotherapies Are Accelerating Personalized Care
Most experts agree on one thing: tech alone won’t fix the problem. Real change will require better outreach in underserved communities, trusted local partnerships, more diverse data, and real accountability from regulators and drug companies.
The FDA’s plan could still change how trials are run. But whether it actually helps Black patients will depend less on speed than on who is included in the process.
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
